Evidence map›Paper›PMID 41387650›Full record

ArticleDermatology and therapy2026

Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial.

Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Bruce Strober, Melinda Gooderham, Yasuhito Hara and 7 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05174065 (A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Apremilast), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05174065 phase3completednot on this map

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Apremilast (AMG 407) in Japanese Subjects With Palmoplantar Pustulosis (PPP)

TypeinterventionalSponsorAmgenRan2022 to 2024Enrolled176ConditionsPalmoplantar PustulosisArmsApremilast, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Tadashi TeruiNihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi, Tokyo, 173-8610, Japan. terui.tadashi@nihon-u.ac.jp.ORCID http://orcid.org/0000-0002-0275-4311
Yukari OkuboTokyo Medical University, Tokyo, Japan.
Satomi KobayashiSeibo International Catholic Hospital, Tokyo, Japan.
Akimichi MoritaNagoya City University, Nagoya City, Japan.
Shinichi ImafukuFukuoka University, Fukuoka, Japan.
Yayoi TadaTeikyo University, Tokyo, Japan.
Masatoshi AbeSapporo Skin Clinic, Sapporo, Japan.
Bruce StroberCentral Connecticut Dermatology Research, Cromwell, CT, USA.
Melinda GooderhamSKiN Centre for Dermatology, Peterborough, ON, Canada.
Yasuhito HaraPatient Author, Tokyo, Japan.
Wendy ZhangAmgen Inc., Thousand Oaks, CA, USA.
Junichiro ShimauchiAmgen Inc., Thousand Oaks, CA, USA.
Masafumi YaguchiAmgen K.K., Tokyo, Japan.
Takeshi KimuraAmgen K.K., Tokyo, Japan.
Ryuichi OgawaAmgen K.K., Tokyo, Japan.
Hamid AmouzadehAmgen K.K., Tokyo, Japan.
Masamoto MurakamiMiyazaki University, Miyazaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This Summary of Research provides an overview of the results of a phase 3 study that assessed the efficacy and safety of apremilast in Japanese patients with moderate to severe palmoplantar pustulosis (PPP) who had not responded to topical treatment (NCT05174065). Patients were randomized to apremilast or placebo for 16 weeks, after which patients randomized to placebo transitioned to apremilast through 52 weeks. This study showed that apremilast significantly improved PPP clinical severity, symptoms, and patient-reported quality of life compared with placebo after 16 weeks of treatment. The benefits of apremilast were maintained or further improved over 52 weeks of treatment. The most common side effects (experienced by > 10% of patients) included diarrhea, nasopharyngitis, nausea, soft stool, and headache, and were consistent with previous studies of apremilast. Side effects were mainly mild to moderate. The results from this phase 3 study support apremilast as a systemic oral treatment option for patients with PPP with inadequate response to topical treatment, for whom treatment options are limited.

Indexed as

ApremilastClinical trialPalmoplantar pustulosisPhase 3Phosphodiesterase 4 inhibitor

Identifiers

PMID41387650
PMCPMC12936317

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.